Sinovac Research And Development Co., Ltd.

This study tested the safety and immune response of a new version of a 13-valent pneumococcal vaccine in young children. It involved 140 healthy Chinese children, split into two age groups: infants starting at 2 months and children aged 2 to 5 years. The new vaccine was directly …